Business
Aug 21, 2026
Taipei, Taiwan, 21 August 2026 — Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSE Stock Code: 1795), a leading multinational pharmaceutical company, today announced a strategic licensing and commercialization agreement with Alvotech (N...
Business
Aug 19, 2026
Taipei, Taiwan, 19 August 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that its generic version of POMALYST® (pomalidomide) capsules, in 1 mg, 2 mg, 3 mg and 4...
ESG
Aug 18, 2026
Taipei, Taiwan, 18 August 2026 — Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSE Stock Code: 1795), a leading multinational pharmaceutical company, proudly announces that it has been named a recipient of the HR Asia Best Companies to ...
Investors
Aug 13, 2026
Taipei, Taiwan, 13 Aug 2026 — Lotus Pharmaceutical (1795:TT; “Lotus” or “the Company”), a multinational pharmaceutical company, announced its financial results for the first half and second quarter ended 30 June 2026, se...
Investors
Aug 10, 2026
Taipei, Taiwan, 10 August 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenue for July 2026 of NT$2,492 million, representi...
.jpg)
ESG
Jul 29, 2026
Taipei, Taiwan and Seoul, South Korea, 29 July 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795, “Lotus” or the “Company”), a global pharmaceutical company headquartered in Taiwan, today announced that ...
